Top-Rated StocksTop-RatedNASDAQ:LEGN Legend Biotech (LEGN) Stock Price, News & Analysis → Your Money is Not Safe (From American Alternative) (Ad) Free LEGN Stock Alerts $56.09 -0.84 (-1.48%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$55.00▼$56.8750-Day Range$55.06▼$69.9952-Week Range$44.52▼$77.32Volume661,678 shsAverage Volume1.08 million shsMarket Capitalization$9.26 billionP/E RatioN/ADividend YieldN/APrice Target$82.76 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Legend Biotech alerts: Email Address Legend Biotech MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.85 Rating ScoreUpside/Downside47.5% Upside$82.76 Price TargetShort InterestBearish6.37% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.16Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.39) to $0.12 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.66 out of 5 starsMedical Sector500th out of 939 stocksPharmaceutical Preparations Industry241st out of 444 stocks 4.4 Analyst's Opinion Consensus RatingLegend Biotech has received a consensus rating of Moderate Buy. The company's average rating score is 2.85, and is based on 11 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $82.76, Legend Biotech has a forecasted upside of 47.5% from its current price of $56.09.Amount of Analyst CoverageLegend Biotech has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 0.0 Short Interest Percentage of Shares Shorted6.37% of the outstanding shares of Legend Biotech have been sold short.Short Interest Ratio / Days to CoverLegend Biotech has a short interest ratio ("days to cover") of 10.8, which indicates bearish sentiment.Change versus previous monthShort interest in Legend Biotech has recently increased by 2.44%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldLegend Biotech does not currently pay a dividend.Dividend GrowthLegend Biotech does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LEGN. Previous Next 3.4 News and Social Media Coverage News SentimentLegend Biotech has a news sentiment score of 1.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Legend Biotech this week, compared to 4 articles on an average week.Search Interest7 people have searched for LEGN on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Legend Biotech to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Legend Biotech insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.02% of the stock of Legend Biotech is held by insiders.Percentage Held by Institutions70.89% of the stock of Legend Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Legend Biotech are expected to grow in the coming year, from ($1.39) to $0.12 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Legend Biotech is -37.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Legend Biotech is -37.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLegend Biotech has a P/B Ratio of 8.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad American AlternativeYour Money is Not SafeBiden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…CLICK HERE TO GET YOUR GUIDE NOW About Legend Biotech Stock (NASDAQ:LEGN)Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.Read More LEGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LEGN Stock News HeadlinesMarch 29, 2024 | finance.yahoo.comManagement’s Conservative Guidance Led Legend Biotech Corporation (LEGN) to Decline in Q4March 24, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Legend Biotech (LEGN)March 29, 2024 | American Alternative (Ad)Your Money is Not SafeBiden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…March 20, 2024 | benzinga.comGenScript Losses Shrink On Strong Growth For Cancer Cell TherapyMarch 19, 2024 | finance.yahoo.comLegend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) ReportMarch 19, 2024 | americanbankingnews.comLegend Biotech's (LEGN) "Buy" Rating Reaffirmed at HC WainwrightMarch 19, 2024 | americanbankingnews.comLegend Biotech (NASDAQ:LEGN) Given New $81.00 Price Target at UBS GroupMarch 16, 2024 | nasdaq.comGuru Fundamental Report for LEGNMarch 29, 2024 | American Alternative (Ad)Your Money is Not SafeBiden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…March 15, 2024 | msn.comJohnson & Johnson wins FDA AdCom backing for Carvykti label expansionMarch 15, 2024 | businesswire.comCARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple MyelomaMarch 15, 2024 | seekingalpha.comLegend Biotech: AdCom Documents Shed Light On Carvykti's Problems (Downgrade)March 12, 2024 | msn.comCompany News for Mar 12, 2024March 12, 2024 | finance.yahoo.comLegend Biotech Corporation (NASDAQ:LEGN) Q4 2023 Earnings Call TranscriptMarch 11, 2024 | seekingalpha.comLegend Biotech Corporation 2023 Q4 - Results - Earnings Call PresentationMarch 11, 2024 | markets.businessinsider.comLegend Biotech Corporation Q4 Loss beats estimatesMarch 11, 2024 | businesswire.comLegend Biotech Reports Fourth Quarter and Full Year 2023 Results and Recent HighlightsMarch 8, 2024 | msn.comLegend Biotech FY 2023 Earnings PreviewMarch 7, 2024 | markets.businessinsider.comWhat 4 Analyst Ratings Have To Say About Legend BiotechMarch 6, 2024 | ca.finance.yahoo.comLEGN Jun 2024 100.000 putMarch 6, 2024 | ca.finance.yahoo.comLEGN Dec 2024 100.000 callMarch 3, 2024 | investing.comLegend Biotech Corp (LEGN)March 2, 2024 | au.finance.yahoo.comLegend Biotech Corporation (LEGN)February 25, 2024 | msn.comJohnson & Johnson wins EU backing to expand labeling for CAR-T therapyFebruary 24, 2024 | finance.yahoo.comAn Intrinsic Calculation For Legend Biotech Corporation (NASDAQ:LEGN) Suggests It's 47% UndervaluedFebruary 23, 2024 | msn.comLegend Biotech stock rises after EU backs label expansion for multiple myeloma therapyFebruary 23, 2024 | businesswire.comLegend Biotech Announces Positive CHMP Opinion for CARVYKTI® (ciltacabtagene autoleucel) for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of TherapySee More Headlines Receive LEGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Legend Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/11/2024Today3/28/2024Next Earnings (Estimated)5/16/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:LEGN CUSIPN/A CIK1801198 Webwww.legendbiotech.com Phone732-317-5050FaxN/AEmployees1,390Year FoundedN/APrice Target and Rating Average Stock Price Target$82.76 High Stock Price Target$94.00 Low Stock Price Target$64.00 Potential Upside/Downside+47.5%Consensus RatingModerate Buy Rating Score (0-4)2.85 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($1.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-518,250,000.00 Net Margins-181.75% Pretax Margin-182.41% Return on Equity-37.19% Return on Assets-25.34% Debt Debt-to-Equity Ratio0.22 Current Ratio6.92 Quick Ratio6.83 Sales & Book Value Annual Sales$285.14 million Price / Sales32.47 Cash FlowN/A Price / Cash FlowN/A Book Value$6.88 per share Price / Book8.15Miscellaneous Outstanding Shares165,067,000Free Float165,034,000Market Cap$9.26 billion OptionableOptionable Beta0.04 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Ying Huang Ph.D. (Age 51)CEO & Director Mr. Doug WallaceVice President of Global OperationsDr. Guowei Fang Ph.D.Chief Scientific Officer & Head of Business DevelopmentJoanne ChoiSenior Manager of Investor RelationsMr. James Pepin J.D.General CounselDeborah WongExecutive Director of Strategic Marketing & Corporate CommunicationsMs. Elaine QianVP & Global Head of Human ResourcesDr. Yuhong Qiu Ph.D.Senior Vice President of Global Regulatory AffairsMr. Steven J. GavelSenior Vice President of Commercial Development, US & EuropeMr. Alan KickSenior Vice President of Global QualityMore ExecutivesKey CompetitorsAscendis Pharma A/SNASDAQ:ASNDCatalentNYSE:CTLTRoivant SciencesNASDAQ:ROIVViking TherapeuticsNASDAQ:VKTXElanco Animal HealthNYSE:ELANView All CompetitorsInstitutional OwnershipPNC Financial Services Group Inc.Sold 322 shares on 3/22/2024Ownership: 0.001%Vanguard Group Inc.Bought 13,821 shares on 3/11/2024Ownership: 0.078%Wellington Management Group LLPBought 962,381 shares on 3/5/2024Ownership: 1.269%Krane Funds Advisors LLCBought 451 shares on 2/26/2024Ownership: 0.011%Chicago Partners Investment Group LLCSold 718 shares on 2/23/2024Ownership: 0.002%View All Institutional Transactions LEGN Stock Analysis - Frequently Asked Questions Should I buy or sell Legend Biotech stock right now? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Legend Biotech in the last year. There are currently 2 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" LEGN shares. View LEGN analyst ratings or view top-rated stocks. What is Legend Biotech's stock price target for 2024? 13 Wall Street research analysts have issued 1 year target prices for Legend Biotech's stock. Their LEGN share price targets range from $64.00 to $94.00. On average, they expect the company's stock price to reach $82.76 in the next twelve months. This suggests a possible upside of 47.5% from the stock's current price. View analysts price targets for LEGN or view top-rated stocks among Wall Street analysts. How have LEGN shares performed in 2024? Legend Biotech's stock was trading at $60.17 at the beginning of the year. Since then, LEGN stock has decreased by 6.8% and is now trading at $56.09. View the best growth stocks for 2024 here. When is Legend Biotech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 16th 2024. View our LEGN earnings forecast. How were Legend Biotech's earnings last quarter? Legend Biotech Co. (NASDAQ:LEGN) posted its quarterly earnings data on Monday, March, 11th. The company reported ($0.40) earnings per share for the quarter, topping analysts' consensus estimates of ($0.70) by $0.30. The firm earned $76.50 million during the quarter, compared to the consensus estimate of $95.63 million. Legend Biotech had a negative net margin of 181.75% and a negative trailing twelve-month return on equity of 37.19%. The company's revenue for the quarter was up 177.2% compared to the same quarter last year. What ETFs hold Legend Biotech's stock? ETFs with the largest weight of Legend Biotech (NASDAQ:LEGN) stock in their portfolio include Global X MSCI China Health Care ETF (CHIH), Loncar China Biopharma ETF (CHNA), Harbor Health Care ETF (MEDI), Fidelity Disruptive Medicine ETF (FMED), Virtus LifeSci Biotech Products ETF (BBP), KraneShares MSCI All China Health Care Index ETF (KURE), BlackRock Future Health ETF (BMED) and Range Cancer Therapeutics ETF (CNCR). What other stocks do shareholders of Legend Biotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other Legend Biotech investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), CrowdStrike (CRWD), Lam Research (LRCX), ServiceNow (NOW), Peloton Interactive (PTON), QUALCOMM (QCOM), Applied Materials (AMAT), DocuSign (DOCU) and Etsy (ETSY). When did Legend Biotech IPO? Legend Biotech (LEGN) raised $350 million in an IPO on Friday, June 5th 2020. The company issued 18,400,000 shares at a price of $18.00-$20.00 per share. Morgan Stanley, J.P. Morgan Securities and Jefferies served as the underwriters for the IPO. Who are Legend Biotech's major shareholders? Legend Biotech's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (5.95%), Hhlr Advisors LTD. (3.29%), Capital World Investors (1.31%), Wellington Management Group LLP (1.27%), Massachusetts Financial Services Co. MA (1.09%) and Capital International Investors (1.00%). How do I buy shares of Legend Biotech? Shares of LEGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LEGN) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeYour Money is Not SafeAmerican AlternativeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaOnly a fool would buy Nvidia today… Porter & CompanyThe ONE AI Sock to own now. (It’s not Nvidia.)Weiss RatingsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Legend Biotech Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.